FDA
EMA
MHRA
PMDA
Health Canada

Clinical

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Competitive

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Markets

Pricing
Access
Commercial
Launch Tracking

M&A Watch

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

Intelligence powered by the Humanexa engine.

Asset / Drug

TRUTAKNA

Drug and asset intelligence for TRUTAKNA with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 2
Stage: Development stage unavailable

Sponsor company

Vera Therapeutics →

Mechanism of action

Monoclonal Antibody

Recent signals(2)

RegulatoryJuly 12, 2026

FDA Grants Priority Review for TRUTAKNA (BLA761486) by Vera Therapeutics

The FDA has granted priority review status for TRUTAKNA, an application submitted by Vera Therapeutics.

RegulatoryJuly 8, 2026

FDA Approves Trutakna for Proteinuria in Primary IgA Nephropathy

The FDA has approved Trutakna (atacicept-vymj) for reducing proteinuria in adults with primary IgA nephropathy.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts

(2)

Topline Data

— TRUTAKNA

July 12, 2026 · N/A

Topline Data

— Trutakna

July 8, 2026 · N/A

Indications

No related entities indexed yet.

Therapeutic areas

Immunology →

Immunology · Monoclonal Antibody →

Monoclonal Antibody →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.